Podcast Summary: What's Your Number?
Episode: Is AI Drug Discovery Finally Here? — with Daphne Koller
Date: February 4, 2026
Hosts: Yonatan Adiri and Yael Wissner-Levy (Ark Media)
Guest: Daphne Koller (Founder & CEO, Insitro)
Episode Overview
This episode explores the intersection of artificial intelligence and biotech, focusing on AI-driven drug discovery. Featuring renowned computer scientist and entrepreneur Daphne Koller, the show unpacks her journey from launching Coursera to founding Insitro, the recent acquisition of Israeli startup Combinable AI, and what the future holds for AI in medicine. The conversation also touches on Israel’s unique tech ecosystem, evolving global talent flows, and the real-world impact of deep tech innovation.
Key Discussion Points & Insights
The Numbers of the Week & Market Pulse
[01:12–04:42]
- Israeli Tech Funding:
- $1 billion raised by Israeli startups in January 2026—strongest start in years.
- "It's the strongest January for Israeli tech since 2022." — Yael [01:14]
- Sports Milestone:
- First Israeli NBA All Star, Danny Avdia (#8)—“an inspiration” for the national psyche and a sign of broader commitment to sports.
- The “Windex” Public Tech Index:
- Israeli companies underperform the NASDAQ; highlights include Nova Measurements (semiconductors, up 8%), Fiverr's recovery, and steep losses for Monday.com due to AI-driven SaaS headwinds.
Israeli Tech M&A & Deep Tech Moves
[09:10–14:30]
- Apple’s Acquisition of Qai:
- Nearly $2B deal for a stealth startup using facial micro-movement tech for wearables.
- Emphasizes Israel’s status as a mature, high-repeat-value tech ecosystem.
- Illustrates that innovation flows from people, not just funding: “Tech is not about where you pour money and you just grow tech... It is not that easy.” – Yonatan [11:51]
- Story of Founder Resilience:
- Qai’s team continued working through wartime disruptions after October 7th: "This slowed them down less than I could have imagined... Not once did they... complain." – Quoting Tom Hulme, investor [41:38]
Global Shifts and Institutional Uncertainty
[14:30–19:29]
- UN’s Financial Crisis:
- Hosts debate whether a weakened UN risks being "rescued" by powers with illiberal agendas.
- The importance of international institutions for small, export-driven economies like Israel.
- Monetary Power in Flux:
- Discussion on the waning dominance of the US dollar, China’s aspirations, and the necessity for structural reforms for real change.
Main Interview: Daphne Koller on AI and Drug Discovery
[19:29–41:29]
From Coursera to Insitro: Lessons in Digital Transformation
[20:16–23:12]
- Koller reflects on the optimism—and slower-than-expected change—sparked by online education:
- “People always overestimate the effect of any new technology at the two-year timeframe and underestimate its effect on a ten-year timeframe.” — Daphne Koller [22:42]
- She draws parallels to drug discovery, warning against hype and underlining the slower, but potentially deeper, impacts of AI in the field.
Global Talent & Israel’s Position in Science
[23:12–28:15]
- Technological and educational leadership cycles across countries (US, Israel, Germany, China).
- Israel’s Talent Model:
- Military and academia identified and cultivated top talent beyond the formal education system.
- The Western world must be deliberate to retain its edge as China scales and iterates with increasing sophistication.
- "If the Western world wants to retain a leadership or co-leadership position, it has to be a deliberate and thoughtful effort." — Daphne Koller [27:44]
What Problem Is Insitro Solving?
[28:15–30:46]
- Most diseases don’t have effective treatments; ALS has four drugs, but none materially extend life.
- Drug development process is long, expensive, and beset by failure: “When a new mechanism goes into the clinic... 90% of those fail.” — Daphne Koller [28:49]
- Insitro’s thesis: Use large-scale, high-fidelity biological data and AI to discover targets unbiasedly, replacing guesswork.
Regulatory & Strategic Focus
[30:46–32:44]
- Diseases like ALS are target-rich partly due to regulatory openness where there are few/no effective treatments.
- "We put together a multiparty rubric for selecting our indications. At the top of our list, it's both unmet need and a differentiated ability..." — Daphne Koller [31:34]
The Combinable AI Acquisition
[32:44–35:36]
- Insitro’s core “virtual human” engine identifies drug targets; Combinable adds missing muscle in biologics (large-molecule drugs).
- Acquisition justified by both tech and talent: "It wasn’t just about the technology. It was also about the people..." — Daphne Koller [33:55]
- Expresses confidence in the Israeli R&D landscape—proving deep tech talent isn’t limited to cyber.
Israel’s Edge in Bioinformatics & AI
[35:36–38:43]
- Israel “disproportionate” in impact thanks to cross-disciplinary programs and a tradition of excellence in computer science.
- The future of biology is at the intersection with AI:
- "Biology is really, really complicated and has lacked a formal foundation... I believe that framework will be AI." — Daphne Koller [37:44]
- Calls for “bilingual” scientists who can bridge strong computing skills and biological problem understanding.
AI’s Impact on Longevity & Healthspan
[38:43–41:29]
- Immortality is not the goal; meaningful increases in “healthspan” and “lifespan” are plausible.
- The path forward is iterative—“a comparable game of whack-a-mole.”
- Strong encouragement for more computer scientists to move into health, agtech, and climate-tech:
- “I think more computer scientists should pursue a career that explicitly aims to make the world a better place.” — Daphne Koller [40:51]
Notable Quotes & Memorable Moments
- Koller on Tech Hype:
- “People always overestimate the effect of any new technology at the two-year timeframe and underestimate its effect on a ten-year timeframe.” [22:42]
- On Drug Development Realities:
- “There is no other industry that has the same kind of failure rates except for space travel. But then space travel got really good. So now we stand alone.” — Daphne Koller [28:49]
- On Israel's Talent Engine:
- “Israel has actually, when I grew up, I was actually pretty good at it. And that I wouldn't necessarily attribute that to our education system as much as to the military.” [25:27]
- On AI in Biology:
- “I believe that that framework will be AI because it's only with... computational power and ability to absorb massive amounts of data that we will be able to make predictions in biology that have a reasonable chance of turning out to be true.” [37:44]
- Investor Testimony on Israeli Founders:
- “This slowed them down less than I could have imagined... Not once did they... complain. Instead, their energy was focused on supporting their community and making technical breakthroughs.” — Tom Hulme, GV [41:38]
Timestamps for Key Segments
- 01:12 — Numbers of the Week (tech funding, sports milestone)
- 04:42 — Windex & Israeli public tech performance
- 09:10 — Israel’s public/private tech and government AI alliance (AI park news)
- 10:28 — Apple’s acquisition of Qai and founder backgrounds
- 14:30 — UN’s financial crisis & implications for Israeli/global affairs
- 19:29 — Introduction to Daphne Koller & main interview
- 20:16 — Lessons from Coursera; tech cycle reflections
- 23:12 — Global talent, China’s rise, Israel’s unique trajectory
- 28:15 — What Insitro does: the problem of AI-driven drug discovery
- 30:46 — Regulatory strategies in new drug development
- 32:44 — Insitro + Combinable AI: deal rationales and Israel’s deep tech talent
- 35:36 — Israel’s edge in bioinformatics and cross-disciplinary science
- 38:43 — AI, longevity, and the real-world pace of healthspan innovation
- 41:38 — Investor reflections on resilience of Israeli founders
Conclusion
The episode offers a rich, forward-thinking look at the future of biotech, the critical role of talent and ecosystem in innovation, and the practical challenges and promises of AI-driven health breakthroughs. Daphne Koller provides hard-won wisdom for anyone interested in where science, technology, and global competition are headed next, while the hosts situate Israel’s story within the broader global currents of technological change and resilience.